Outpace Bio is a biotech startup that is revolutionizing cell therapy through innovative protein design. The company aims to cure solid tumors by creating new proteins that can guide cells to recognize and eliminate cancer in the body. The company's founders have pioneered a new era in protein design, shifting from designing structures to creating new biological functions.

Outpace Bio's business model revolves around solving three key problems in curing solid tumors: the tumor's suppression of our immune response, the limited persistence of cell therapy, and the limited potency, safety, and specificity of cell therapy. To address these issues, the company has developed technologies that stimulate productive immune responses, enable potent and persistent cell therapy activity, and maximize the potency, safety, and specificity of cell therapies across diverse cancer indications.

The company uses AI-powered protein design to create proteins that program engineered cells for improved function inside patients. These proteins are then combined to develop cell therapy products with curative potential. Outpace Bio's platform technologies can power any cell type and manufacturing approach, making it a versatile player in the biotech industry.

The company operates in the biotech market, serving clients in the medical and healthcare sectors. It generates revenue by developing and selling its innovative cell therapy products and technologies.

Keywords: Biotech, Cell Therapy, Protein Design, Cancer Treatment, AI-Powered, Solid Tumors, Immune Response, Potency, Safety, Specificity.